Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70285 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Jorge J Castillo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Piperidines, Adenine, Sulfonamides, Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: AbbVie, Pharmacyclics.
Abstract (Originalsprache)
The BTK inhibitor ibrutinib and the BCL‐2 antagonist venetoclax are active therapies as single agents in Waldenström macroglobulinemia (WM). In this phase 2 study, we sought to investigate the combination of ibrutinib and venetoclax as a 2‐year fixed‐duration, oral‐based, chemotherapy‐free regimen in symptomatic, treatment‐naive WM patients. All patients had MYD88 mutations, 17 (38%) had CXCR4 mutations, and 4 (9%) had TP53 alterations. Following enrollment of 45 patients, treatment and enrollment were stopped due to the occurrence of ventricular arrhythmias in 4 (9%), which included two grade 5 events. The median treatment time was 10 cycles, each lasting 28 days. Follow‐up continued after protocol treatment was terminated. The very good partial response/complete response (VGPR/CR) rate was 42%, and it was lower in patients with CXCR4 (29% vs. 50%) or TP53 (25% vs. 44%) mutations. With a median follow‐up of 49 months, the median progression‐free survival (PFS) was 36 months (range 28–42). The median treatment‐free survival (TFS) and overall survival (OS) were not reached, and the 4‐year TFS and OS rates were 73% and 91%, respectively. The median PFS after end of therapy (PFS‐EOT) was 29 months. TP53 mutations were associated with inferior PFS, TFS, and PFS‐EOT, while CXCR4 mutations did not adversely impact these outcomes. Given the deep and durable responses seen in this study, concurrent BTK and BCL‐2 inhibition warrants further development in WM. TP53 mutations emerged as an adverse factor in WM in this combination study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Center for Multiple Myeloma, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Medicine, Roger Williams Medical Center, Boston University Chobanian & Avedisian School of Medicine, Providence, Rhode Island, USA.
ORCID-Profile: Jorge J Castillo, Andrew R Branagan, Alberto Guijosa, Gottfried von Keudell, Andres Ramirez-Gamero, Maria Luisa Guerrera, Shirong Liu, Zachary R Hunter, Steven P Treon, Shayna Sarosiek
Förderung
- AbbVie
- Pharmacyclics
Zitieren
APA
Castillo, J. J., Branagan, A. R., Guijosa, A., von Keudell, G., Ramirez-Gamero, A., Chory, H., Kobs, M., Budano, N., Nguyen, J., Eurell, A., Boyajian, C., Meid, K., Guerrera, M. L., Kofides, A., Liu, S., Liu, X., Tsakmaklis, N., Hunter, Z. R., Patterson, C. J., …, & Sarosiek, S. (2026). Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia. American Journal of Hematology. https://doi.org/10.1002/ajh.70285
Vancouver
Castillo JJ, Branagan AR, Guijosa A, von Keudell G, Ramirez-Gamero A, Chory H, et al. Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia. American Journal of Hematology. 2026. doi:10.1002/ajh.70285
BibTeX
@article{Castillo2026,
author = {Castillo, Jorge J and Branagan, Andrew R and Guijosa, Alberto and von Keudell, Gottfried and Ramirez-Gamero, Andres and Chory, Hannah and Kobs, Margaret and Budano, Nina and Nguyen, Julia and Eurell, Alexandra and Boyajian, Courtney and Meid, Kirsten and Guerrera, Maria Luisa and Kofides, Amanda and Liu, Shirong and Liu, Xia and Tsakmaklis, Nicholas and Hunter, Zachary R and Patterson, Christopher J and Treon, Steven P and Sarosiek, Shayna},
title = {Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70285}
}
EUVIMED